Overview

A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

Status:
Completed
Trial end date:
2013-01-25
Target enrollment:
Participant gender:
Summary
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in participants with overactive bladder and to guide recommendations on potential dosing adjustments for individuals with varying degrees of renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.